Skip to main content

Zaccardelli David's Form 4 filing

Verona Pharma plc (VRNA) · filed Aug 14, 2024

Accession no.
0001104659-24-089644
Filed
Aug 14, 2024
Trade date
Aug 12-13, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $1.28M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Zaccardelli DavidCIK 0001627642Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 12, 2024Ordinary SharesSSaleDisposed−1,600$3.13F3−$5,00816,249,104Direct
Aug 13, 2024Ordinary SharesSSaleDisposed−390,184$3.20F4−$1,248,588.815,858,920Direct
Aug 13, 2024Ordinary SharesSSaleDisposed−8,216$3.25F3−$26,70215,850,704Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported represents the ADS sale price on the Nasdaq Stock Market LLC divided by eight (8).

Referenced by the price of 2 transactions in Table I.

F4

The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $3.125 to $3.246875 per Ordinary Share, inclusive (or $25.00 to $25.99 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)